PEL

Piramal Enterprises Share Price

₹1,012.30 -10.85 (-1.06%)

14 Nov, 2024 08:58

SIP TrendupStart SIP in PEL

Start SIP

Performance

  • Low
  • ₹994
  • High
  • ₹1,024
  • 52 Week Low
  • ₹737
  • 52 Week High
  • ₹1,144
  • Open Price₹1,020
  • Previous Close₹1,023
  • Volume943,984

Investment Returns

  • Over 1 Month -6.25%
  • Over 3 Month + 2.73%
  • Over 6 Month + 22.44%
  • Over 1 Year + 7.08%
SIP Lightning

Smart Investing Starts Here Start SIP with Piramal Enterprises for Steady Growth!

Invest Now

Piramal Enterprises Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -12
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 22,825
  • P/B Ratio
  • 0.9
  • Average True Range
  • 37.34
  • EPS
  • 0
  • Dividend Yield
  • 1
  • MACD Signal
  • -0.44
  • RSI
  • 39.59
  • MFI
  • 61.63

Piramal Enterprises Technicals

EMA & SMA

Current Price
₹1,012.30
-10.85 (-1.06%)
pointer
  • stock-down_img
  • Bullish Moving Average 3
  • stock-up_img
  • Bearish Moving Average 13
  • 20 Day
  • ₹1,052.92
  • 50 Day
  • ₹1,047.85
  • 100 Day
  • ₹1,017.68
  • 200 Day
  • ₹983.08

Resistance and Support

1010.07 Pivot Speed
  • R3 1,055.88
  • R2 1,039.87
  • R1 1,026.08
  • S1 996.28
  • S2 980.27
  • S3 966.48

What's your outlook on Piramal Enterprises?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Piramal Enterprises Ltd. is a diversified company with interests in financial services and pharmaceuticals. It provides lending solutions, asset management, and healthcare products, serving a wide range of customers across India and global markets.

Piramal Enterprises has an operating revenue of Rs. 9,359.71 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of -34% needs improvement, ROE of -6% is poor and needs improvement. The stock from a technical standpoint is trading below to its 50DMA and around 8% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 11% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 38 which is a POOR score indicating inconsistency in earnings, a RS Rating of 59 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 125 indicates it belongs to a poor industry group of Finance-Commercial Loans and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Piramal Enterprises Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-23 Quarterly Results
2024-08-13 Quarterly Results
2024-05-08 Audited Results & Final Dividend
2024-01-29 Quarterly Results
2023-11-09 Quarterly Results
Date Purpose Remarks
2024-07-05 FINAL Rs.10.00 per share(500%)Final Dividend
2023-06-16 FINAL Rs.31.00 per share(1550%)Final Dividend
2022-07-15 FINAL Rs.33.00 per share(1650%)Final Dividend
2021-07-07 FINAL Rs.33.00 per share(1650%)Final Dividend

Piramal Enterprises F&O

Piramal Enterprises Shareholding Pattern

46.3%
7.78%
5.16%
14.93%
0%
16.57%
9.26%

About Piramal Enterprises

Piramal Enterprises Limited is an Indian multinational pharmaceutical and financial services company based in Mumbai, Maharashtra. Founded by Ajay Piramal (who is also the Chairman), the company operates in the pharmaceuticals, financial services and real estate sector.

He founded the company in 1984 after he acquired a small-scale manufacturing unit from his father. Today, Piramal has more than 50 offices across 30 countries and employs over 10,000 people worldwide. With a presence in 100+ countries through its subsidiaries or associate companies. Piramal has been ranked among Forbes Asia’s 200 Best Under A Billion in 2019.

Business Verticals

PEL's Global Pharma division has a strong product portfolio of niche differentiated branded generics that are difficult to manufacture, sell, or distribute. Through its worldwide network of facilities, PEL's Contract Development and Manufacturing Organisation (CDMO) services segment provide end-to-end solutions across the drug life cycle. 

The Indian consumer products division of PEL serves India’s self-care market. PEL's OTC portfolio includes 21 major pharmaceutical and personal care brands in diverse product categories such as Vitamins & Nutrition, Dermatological & Antacids, Analgesics, and Baby Care. PEL's Healthcare Insights & Analytics division is the world's leading provider of healthcare analytics data, insight products and services to the world's leading pharma, biotech and medical technology companies, allowing them to make informed business decisions.

PEL's financial services include wholesale lending, housing finance, and alternative asset management. Piramal Capital & Housing Finance Ltd, PEL's wholly-owned subsidiary, is registered as a housing finance company with National Housing Bank (NHB) and is involved in a variety of financial services businesses. It offers wholesale and retail funding opportunities across industries.

Company History

Piramal Enterprises was founded as Indian Schering Limited on April 26, 1947, by British Schering Ltd. With effect from September 27, 1979, the company's name was changed from Indian Schering Ltd to Nicholas Laboratories India Ltd. Gujarat Glass Ltd (GGL) was acquired with the company on April 1, 1990. The new formulation plant in Pithampur, Madhya Pradesh, was inaugurated in 1991. After a year, in 1992, the company established a second formulation plant in Pithampur, Madhya Pradesh, with cutting-edge manufacturing facilities. The company's name changed from 'Nicholas Laboratories Ltd' to 'Nicholas Piramal India Ltd' on December 2, 1992.
 

Milestones

1988
Entered the pharmaceutical industry with the purchase of Nicholas Laboratories.
A series of mergers and acquisitions, joint ventures and alliances, and organic initiatives.

2010
Over two decades, they built a leading Indian pharmaceutical company.
The Domestic Formulations business was sold to Abbott in 2010 for USD 3.8 billion. Diagnostic Services were sold to Super Religare Laboratories.

From 2020 onwards
Multiple capital raise initiatives helped to strengthen the balance sheet.
Through the sale of DRG and the exit of Shriram Transport, the organization structure was simplified.
Subsidized the pharmaceutical businesses and raised new capital from Carlyle Transforming Financial Services with the DHFL acquisition to deliver long-term growth and profitability.
 

View More
  • NSE Symbol
  • PEL
  • BSE Symbol
  • 500302
  • ISIN
  • INE140A01024

Similar Stocks to Piramal Enterprises

Piramal Enterprises FAQs

Piramal Enterprises share price is ₹1,012 As on 14 November, 2024 | 08:44

The Market Cap of Piramal Enterprises is ₹22825.1 Cr As on 14 November, 2024 | 08:44

The P/E ratio of Piramal Enterprises is -12 As on 14 November, 2024 | 08:44

The PB ratio of Piramal Enterprises is 0.9 As on 14 November, 2024 | 08:44

Piramal Enterprises Ltd recorded net sales of INR 13993 crores in the year ending March 2022. 

Piramal Enterprises Ltd stock may be a good buy according to market analysts considering meaningful inroads into Retail led by mortgages and small-term loans via digital alliance.

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23